CC
LRMR icon

Commodore Capital’s Larimar Therapeutics LRMR Stock Holding History

Commodore Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750,000
Closed -$3.1M – 38
2022
Q4 		$3.1M Hold
750,000
– – 0.47% 30
2022
Q3 		$2.4M Buy
+750,000
New +$1.88M 0.39% 29

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Commodore Capital's LRMR Position: Q1 2023 in Review

Commodore Capital sold out of Larimar Therapeutics (LRMR) in Q1 2023, closing a stake of 750,000 shares — an estimated $3.1M sold.

Commodore Capital first reported a position in LRMR in Q3 2022 and held it in 2 quarters. The position peaked at $3.1M in Q4 2022. 68 funds tracked by Wall St. Rank hold LRMR as of Q1 2023.

  • Commodore Capital reported no remaining Larimar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Commodore Capital sold 750,000 Larimar Therapeutics shares in Q1 2023, an estimated $3.1M.
  • Commodore Capital first reported a position in Larimar Therapeutics in Q3 2022 and held it in 2 quarters.
  • Commodore Capital's Larimar Therapeutics position peaked at $3.1M in Q4 2022.
  • 68 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2023.

Based on Commodore Capital's 13F filing for Q1 2023, filed 15 May 2023.